🇺🇸 FDA
Patent

US 12264158

Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

granted A61PA61P1/16A61P19/02

Quick answer

US patent 12264158 (Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death) held by HEPAREGENIX GMBH expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
HEPAREGENIX GMBH
Grant date
Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61P, A61P1/16, A61P19/02, A61P25/00